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Background: Poor treatment adherence among leprosy patients contribute to relapse, development of antimicrobial resistance, and the eventual plateauing of the prevalence and incidence of leprosy not just in the Philippines,
but also worldwide. For this reason, we aimed to identify the patterns and determinants affecting treatment
completion and default among multibacillary leprosy patients.
Methods: We conducted a retrospective cohort study involving three large hospitals in Metro Manila, Philippines.
Patients who started the World Health Organization - Multiple Drug Therapy for multibacillary leprosy between
January 1, 2007 and December 31, 2013 were included in the study. Selected socio-demographic and clinical data
were abstracted from the patient treatment records. Survival analysis and proportional hazards regression were
used to analyze the data.
Results: Records of 1,034 patients with a total follow-up time of 12,287 person-months were included in the
analysis. Most patients were male, younger than 45 years old, had an initial bacterial index between 1 and 4, and
were residents of Metro Manila. Less than 20% had their treatment duration extended to more than 12 months.
Treatment adherence of the patients was poor with less than 60% completing treatment. Most patients complete
their treatment within 12 months, but treatment duration may be extended for up to three years. Patients who
default from treatment usually do so a few months after initiating it. After adjusting for other variables, hospital,
initial bacterial index, and non-extended treatment duration were associated with treatment completion. These
factors, in addition to age, were also found to be associated with treatment default.
Conclusion: This study provides quantitative evidence that there might be marked variations in how doctors in
particular hospitals manage their patients, and these ﬁndings underscore the need to revisit and re-evaluate
clinical practice guidelines to improve treatment outcomes and adherence.

1. Introduction
Poor treatment adherence among leprosy patients is associated with
relapse and the occurrence of antimicrobial resistance [1]. It has also
been reported to contribute to the plateauing incidence and prevalence of
leprosy in the Philippines [2], and worldwide [3, 4, 5, 6]. A perceived
reason for poor treatment adherence is the long duration of the World
Health Organization (WHO) multiple drug therapy (MDT) regimen,

lasting a year for multibacillary leprosy patients [7, 8], which could even
be extended for up to three years [9, 10]. In addition to the long duration
of treatment, a host of psychosocial, economic, medical and health service, as well as personal factors were found to affect treatment adherence
[11]. Two earlier reviews reported the following factors to be associated
with poor treatment adherence: socio-economic status; educational
attainment; gender; alcohol consumption; knowledge about leprosy;
stigma associated with the disease; cultural factors; transportation costs;
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remoteness of residence; ﬁnancial concerns; adverse effects of MDT;
source of MDT; MDT drug shortages; poor relationship between patient
and healthcare provider; and occurrence of leprosy reactions [1, 12].
A systematic review of factors associated with poor treatment
adherence showed that cohort studies are not frequently used in studying
this phenomena, not to mention, the use of survival analysis to analyze
treatment adherence data [12]. Survival analysis is an analytic tool that
deals with time-to-event data, appropriate for studying varying lengths of
follow-up time to an event of interest [13]. In studying the determinants
of treatment adherence, cohort studies are preferred over the more
commonly-used cross-sectional or case-control designs, as the former
research design allows examination of temporal direction between
exposure and outcome [14]. Furthermore, the beneﬁt of using of survival
analysis to analyze treatment adherence data lies in its ability to account
for varying treatment durations due to defaulting (i.e., dropping out),
extending treatment, or irregular intake of MDT. Survival analysis to
study determinants of treatment adherence has been used to analyze data
on major depressive disorders [15], and on tuberculosis [16, 17] but
none on leprosy, let alone leprosy among Filipino patients. In the Western
Paciﬁc Region, the Philippines has the highest incidence of leprosy, with
around 1,700 new cases being diagnosed each year [18].
Considering the lack of studies on treatment adherence among
leprosy patients, this study investigates treatment completion and
defaulting patterns by using survival analysis. The study also examines
the factors that are associated with treatment completion and treatment
default among newly diagnosed multibacillary leprosy patients in
selected hospitals in Metro Manila, Philippines.

the MDT, as long as they completed the minimum of 12 doses of treatment taken over a maximum of 18 months; if the treatment is extended to
18 months, all the doses should be taken over a 24-month period, and so
on.
On the other hand, treatment default is deﬁned as a patient who has
not completed treatment within the prescribed duration with a six-month
grace period (e.g., if a patient failed to complete 12 MDT doses in 18
months, then that person is considered a defaulter). This deﬁnition was
also applied to patients whose treatment duration was extended to more
than 12 months (e.g., if a patient's treatment was extended to 24 MDT
doses upon the recommendation of his/her physician but failed to take
all 24 doses in 30 months, then the patient will also be considered a
defaulter). While the date of treatment completion should be recorded in
the patient charts and/or logbooks, this data was not often found in
either the patient chart or clinic logbook, especially among defaulters. To
address this problem, we assumed that the date of patient default was the
projected date when the patient would have consumed all the medicines
received during his/her last visit to the clinic. The assumption was one
blister pack would last 28 days (e.g., if the patient last visited on January
31, 2014, and has only claimed an MDT pack for one month, then the
date of default will be listed as February 28, 2014).
We performed survival analysis and conducted separate analyses for
treatment completion and treatment default. If the outcome for the analyses was treatment completion, patients who experienced other outcomes (e.g., died, defaulted, transferred-out, and in-treatment) were
censored. Similarly, if the outcome for the analyses was treatment
default, those who experienced other outcomes (e.g., died, completed
treatment, transferred-out and in-treatment) were likewise censored. For
both outcomes, we considered the following exposure variables: age; sex;
place of residence; the hospital where they got treatment; initial bacterial
index; and treatment extension. The distribution of the study participants
according to categories of each exposure variable and the outcome variable were examined. Kaplan-Meier curves were used to describe treatment completion and defaulting patterns. We used number of months as
the time scale for the analysis of duration of treatment adherence. The
rates of occurrence of each outcome were determined for each level of
the different exposure variables. Any difference in the survival functions
between each level of the exposure variable was assessed using the logrank test [20]. The crude rate ratio for each exposure was determined
using the Mantel-Haenszel method. Once the crude rate ratio for each
exposure variable was estimated, patients with missing data for the
relevant variables were dropped from subsequent analyses. Afterwards,
we used Cox proportional hazards regression to study the effect/s of the
exposures on the outcome variables [21]. For the variables age and BI, we
performed tests for departure-from-linearity-assumption using the likelihood ratio test. We formally tested the proportional hazards assumption
of each resulting model by assessing their Schoenfeld residuals [22].
Should the proportional hazards assumption be violated in any of the
models, Lexis expansion was used to stratify the follow-up time into intervals such that the proportional hazards assumption is satisﬁed [23]. In
this case, separate Cox regression models were made for each interval.
For all statistical tests, a level of signiﬁcance of 0.05 was used [24]. Data
were initially encoded in EpiInfo 3.5.4 [25], while cleaning and data
analyses was carried out in Stata/IC 14.0 [26].

2. Methods
2.1. Study design, population and variables
We utilized a retrospective cohort study by reviewing the clinic records of all newly diagnosed multibacillary leprosy patients aged 15 and
above who commenced WHO-MDT between January 1, 2007 and
December 31, 2013 in three large hospitals (A, B, and C) in Metro Manila,
Philippines. Using the patient charts, we ‘followed’ them up until the end
of their treatment, or until March 1, 2015, whichever came ﬁrst. We
included all patients who met the criteria and for whom we had access to
their records to ensure that we have adequate sample size for our
analyses.
From the patient records, we were given permission to collect the
following data: hospital where they got treatment; age; sex; place of
residence (i.e., Metro Manila or outside); estimated treatment duration
(from the start of treatment to date when they stopped taking MDT);
treatment outcome (i.e., completed treatment, defaulted, transferred-out,
died, or still under treatment by March 1, 2015); and recorded bacterial
index (BI) readings (i.e., initial and subsequent BI data).
2.2. Data management and analysis
To facilitate analyses of possible linear trends, we assigned ‘scores’ to
quantitative categorical variables, such as age of patient and BI. Using the
midpoint of each age group as ‘score’, we categorized the age of patient
into three age groups (15–29, 30–44, and 45 and above) to ensure
adequate sample size per strata [19]. Owing to substantial missing data
on subsequent BI measurements, only the initial BI reading was included
in this analysis. The initial BI data was recoded into three categories
corresponding to the following cut-off values: zero (0); low (1–3); and
high BI [4, 5, 6] which were assigned ‘scores’ of 0, 2, and 5, respectively.
The hospitals included in this study have similar deﬁnitions for
treatment completion but had varying deﬁnitions for treatment default
[9]. Therefore, to ensure consistency, we deﬁned treatment completion
as a patient who has been declared by the hospital as having completed

2.3. Ethics
Only anonymized data were accessed and collected; thus, it was unnecessary to obtain informed consent from individual patients. This study
has received ethical approval from the University of the Philippines
Manila Research Ethics Board (Reference No.: UPMREB 2015-092-UND).
The study has also received ethics approval from each of the participating
hospitals; however, the names of the participating hospitals are not disclosed to maintain their anonymity.
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3. Results

around 57% of the patients completed treatment, and 37% defaulted; the
rest experienced other outcomes (i.e., died, ‘transferred out’ to other
treatment facilities, or were still in-treatment as of March 1, 2015).

3.1. Description of study participants
The cohort consisted of 1,034 records of newly diagnosed multibacillary leprosy patients from the three hospitals that were included in
the study. These patients had a total of 12,286.6 person-months of
observation time and the duration of follow-up ranged from 0 to 39.9
months. Although the number of new leprosy patients seen in each
hospital per year was not available, we describe the patients according to
a few demographic and relevant clinical characteristics (Table 1). Around
three-fourths of the patients were male, while more than two-thirds have
consulted Hospital C. The age of the patients ranged from 15 to 90 years
old, but most were below 45 years old. Initial Bacterial Index (BI) varied
from 0 and 6þ, with 396 (38.3%) having low initial BI, and almost a
similar number, 391 (37.8%), having high initial BI. From the 391 patients who had high initial BI, 103 (26.3%) were advised by their
physician to extend treatment. These 103 patients, together with 74
others, made up the 177 (17%) patients in the entire cohort who were
advised by their physician to extend duration of treatment to 18, 24, 30
or 36 months. This treatment duration is beyond the 12 months of
treatment prescribed by the WHO. Regardless of treatment duration,

3.2. Patterns and determinants of treatment completion

0

139 (13.4)

1–3

396 (38.3)

4-6þ

391 (37.8)

Missing

108 (10.4)

The median time-to-treatment-completion was 13.4 months
(Figure 1). This curve shows the cumulative probability of treatment
completion among those who completed MDT regardless of treatment
duration. In this ﬁgure, each step increase in the curve indicates a patient
completing treatment, while black marks indicate patients who have
experienced outcomes other than treatment completion (i.e., censored
observations). Most of the patients were treated for 12 months, but there
were also some who completed treatment beyond the prescribed 12month period as decided by their physician. The large increase shortly
after the 24th month represent those patients whose treatment duration
was extended to 24 months and who completed the treatment. The
longest recorded duration of treatment was 39.9 months. Without controlling for other variables, and among the exposure variables studied,
the hospital where patients got treatment (p < 0.01), sex (p < 0.01),
initial BI (p < 0.01), and treatment extension status (p < 0.01) were all
signiﬁcantly associated with treatment completion (Table 2).
Prior to doing multivariate analysis, we excluded some 108 (10.4%)
patients who did not have any data for initial BI. Thus, in the multivariate
analysis, we only included data from 926 (89.6%) patients who had
complete data for all the exposure variables of interest. The proportional
hazards model for treatment completion showed that after adjusting for
potential confounders, there was strong evidence that the hospital where
treatment was obtained, initial BI, and treatment extension were all
associated with treatment completion (Table 3). Speciﬁcally, patients
from Hospital C had 28% lower instantaneous rate of treatment
completion (adjusted hazard ratio (aHR): 0.72; 95% Conﬁdence Interval
(CI): 0.59–0.87) compared to those from Hospital A. Similarly, patients
whose treatment was extended had 98% lower instantaneous rate of
treatment completion (aHR: 0.02; 95% CI: 0.01–0.04) compared to those
whose treatment was not extended. Furthermore, the relationship between initial BI readings and treatment completion also did not show a
departure from the linearity assumption (p ¼ 0.58), hence a common
hazard ratio is reported. Each unit increase in initial BI reading translated
to around 7% (aHR: 0.93; 95% CI: 0.89–0.98) decrease in the instantaneous rate of treatment completion. Lastly, the relationship between age
group and treatment completion did not show departure from the linearity assumption (p ¼ 0.89). Thus, a common hazard ratio (aHR: 1.00;
95% CI (CI): 0.99–1.00) estimating a 0.005% decrease in the instantaneous rate of treatment completion per unit increase in age is shown in
the table. There was no strong evidence that the proportional hazards
assumption was violated in this model (p ¼ 0.20).

2007

94 (9.1)

3.3. Patterns and determinants of treatment default

2008

149 (14.4)

2009

140 (13.5)

2010

197 (19.1)

2011

172 (16.6)

2012

151 (14.6)

2013

131 (12.7)

Table 1. Distribution of study participants by selected characteristics (n ¼
1,034).
Variable

Frequency (%)

Hospital
A

238 (23.0)

B

99 (9.6)

C

697 (67.4)

Age group
15–29

358 (34.6)

30–44

386 (37.3)

45þ

290 (28.1)

Sex of Patient
Male

769 (74.4)

Female

265 (25.6)

Place of Residence
Within Metro Manila

633 (61.2)

Outside Metro Manila

401 (38.4)

Initial Bacterial Index

Year started treatment

Many patients who dropped-out from treatment did so within a few
months after initiating it as shown by the steep rise early in the follow-up
(median time to default ¼ 3.6 months; Figure 2). In this ﬁgure, each step
increase in the curve indicates a patient defaulting from treatment, while
black marks indicate patients who have experienced outcomes other than
treatment default. The last patient to drop-out of treatment did so after
about 26 months of follow-up, after he/she failed to ﬁnish the treatment
after his/her treatment duration was extended to 24 months. Unlike
Figure 1, the cumulative probability of treatment default never reached 1
in this Figure because the person with the longest observation time (i.e.,
at 39.9 months) did not default from treatment; the patient actually
completed treatment. Without controlling for other variables and among
the variables considered, only treatment extension status was strongly
associated with treatment default (p < 0.01). Speciﬁcally, patients whose
treatment was not extended had signiﬁcantly higher instantaneous rate

Treatment extension
No treatment extension

857 (82.9)

Yes, treatment extended

177 (17.1)

Treatment outcome
Completed Treatment

590 (57.1)

Died while in treatment

5 (0.5)

Transfer-out

38 (3.7)

Defaulted/dropped-out

383 (37.0)

In-treatment as of March 1, 2015

18 (1.7)
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treatment default. There was no strong evidence that the model for the
ﬁrst six months of follow-up violated the proportional hazards assumption (p ¼ 0.49).
For six months or longer follow-up, we included in the analysis patients from Hospital B and those who had treatment extension. There was
strong evidence that after adjusting for confounders, instantaneous rates
of treatment default differ by hospital, initial bacterial index, and treatment extension. Speciﬁcally, the instantaneous rate of treatment default
was higher in Hospital B (aHR: 2.80; 95% CI: 1.08–7.30) as compared to
Hospital A. There was no departure from the linearity assumption for
initial bacterial index (p ¼ 0.15), and so a common hazard ratio (aHR:
1.15; 95% CI: 1.03–1.29) was used to describe a 15% increase in the
instantaneous rate of treatment default per unit increase in bacterial
index reading. Likewise, there was no departure from the linearity
assumption for age, and a common hazard ratio (aHR: 1.00; 95% CI:
0.98–1.01) is reported to describe the 0.003% decrease in the instantaneous rate of treatment default per year increase in age. Lastly, the
instantaneous rate of treatment default was 81% lower (aHR: 0.19; 95%
CI: 0.10–0.36) among those whose treatment was extended compared to
those whose treatment was not extended. There was no strong evidence
that the proportional hazards assumption was violated by the model for
this period of follow-up (p ¼ 0.18).

Figure 1. Treatment completion pattern of the cohort (n ¼ 1,034).

of treatment default compared to those whose treatment was extended
(Table 4).
In the initial model for this outcome, the proportional hazards
assumption was violated (p < 0.01). Hence, we split follow-up time into
the ﬁrst six months of treatment, and the subsequent 6.1–39.9 months of
observation. To identify the determinants of treatment default for the
ﬁrst six months of follow-up, respondents from Hospital B or those who
had treatment extension, were excluded in the analysis for the reason
mentioned above. For the ﬁrst six months of follow-up, there was no
departure from the linearity assumption for the association between BI
and treatment default (p ¼ 0.21); thus, a common hazard ratio (aHR:
1.02; 95% CI: 0.95–1.10) is reported. After adjusting for confounding
variables, there was a 2% increase in the instantaneous rate of treatment
default per unit increase in initial bacterial index, but this result was not
statistically signiﬁcant. In contrast, there was a departure from the
linearity assumption between age and treatment default (p ¼ 0.04). For
this reason, age-speciﬁc hazard ratios are presented (Table 5). For the
ﬁrst six months of follow-up, there was a strong evidence that being
30–44 years old was protective (aHR: 0.72; 95% CI: 0.53–0.99) against

4. Discussion
This study shows that treatment adherence of newly diagnosed
multibacillary leprosy patients in selected hospitals in Metro Manila,
Philippines is unsatisfactory, with less than 60% completing treatment
and almost 40% defaulting from it. The study also demonstrates that
treatment duration of leprosy patients is sometimes extended, disregarding WHO guidelines [7]. Results also show that many patients who
leave treatment did so in the ﬁrst few months after its start. The study
also provides evidence that the hospital where patients get their treatment, initial BI readings, and having their treatment extended signiﬁcantly affected treatment compliance. In addition to age of the patient,
these same variables were also associated with treatment default. While
most of these ﬁndings only corroborate what is already known from other
similar studies about the determinants of treatment adherence in leprosy

Table 2. Rates of treatment completion and comparison of treatment completion patterns for each level of exposure of interest.
Exposure variable

Number (%) of
Treatment Completers

Person-time
(100 person-months)

Rate of treatment completion
(per 100 person-months) (95% CI)

A

155 (65.1)

27.37

5.66 (4.84–6.63)

B

53 (53.5)

16.21

3.27 (2.50–4.28)

C

382 (54.8)

79.29

4.82 (4.36–5.33)

187 (52.2)

40.62

4.60 (3.99–5.31)

<0.01

Hospital

Age Group
15–29

0.85

30–44

232 (60.1)

47.55

4.88 (4.29–5.55)

45þ

171 (59.0)

34.69

4.93 (4.24–5.73)

Male

428 (55.7)

92.44

4.63 (4.21–5.09)

Female

162 (61.1)

30.42

5.33 (4.57–6.21)

Within Metro Manila

372 (58.8)

75.55

4.92 (4.45–5.45)

Outside Metro Manila

218 (54.4)

47.29

4.61 (4.04–5.26)

96 (69.1)

15.94

6.02 (4.93–7.35)

<0.01

Sex of patient

Place of residence

0.31

<0.01

Initial Bacteria Index Value
0

p-value of
logrank test

1–3

241 (60.9)

43.47

5.54 (4.89–6.29)

4-6þ

205 (52.4)

50.24

4.08 (3.56–4.68)

Missing

48 (44.4)

13.22

3.63 (2.74–4.82)

No treatment extension

457 (53.3)

80.93

5.65 (5.15–6.19)

Yes, treatment extended

133 (75.1)

41.93

3.17 (2.68–3.76)

<0.01

Treatment Extension
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Table 3. Association of hospital, age category, sex address, initial BI category, and treatment extension with treatment completion.
Crude Rate Ratio (95% CI)

p-value

Adjusteda Hazard Ratio (n ¼ 926) (95% CI)

p-value

Hospital
A

1 (baseline)

B

0.58 (0.42–0.79)

<0.01

0.61 (0.34–1.08)

1 (baseline)
0.09

C

0.85 (0.71–1.03)

0.09

0.72 (0.59–0.87)

<0.01

1.00b (0.99–1.00)

Age Group
15–29

1 (baseline)

30–44

1.06 (0.87–1.29)

0.55

1 (baseline)

45þ

1.07 (0.87–1.32)

0.52

0.24

Sex
Male

1 (baseline)

Female

1.15 (0.96–1.38)

1 (baseline)
0.13

0.98 (0.80–1.19)

0.44

0.94 (0.79–1.12)

0.93b (0.89–0.98)

0.83

Place of residence
Within Metro Manila

1 (baseline)

Outside Metro Manila

0.94 (0.79–1.11)

1 (baseline)
0.51

Initial BI
0

1 (baseline)

1–3

0.92 (0.73–1.17)

0.50

1 (baseline)

4-6þ

0.68 (0.53–0.86)

<0.01

<0.01

Treatment extension
Not extended

1 (baseline)

Extended

0.56 (0.46–0.68)

a
b

1 (baseline)
<0.01

0.02 (0.01–0.04)

<0.01

Adjusted for other variables listed in the table.
Common linear effect.

[1, 5, 11, 12], the ﬁndings of our study provide quantitative empirical
evidence that underscores the need to re-evaluate the current clinical
management of multibacillary leprosy patients [9, 27].
It has been previously documented that there are variations in how
hospitals diagnose, manage, and treat the multibacillary leprosy patients,
despite the guidelines from the WHO and the Philippine Department of
Health [9]. This study corroborates and provides quantitative evidence
that such variations result to differences in treatment adherence and
defaulting patterns. Rates of treatment completion are highest, while
rates of treatment default are lowest among patients of Hospital A. The
opposite can be said about Hospital B, however. These ﬁndings support
the need to assess the effectiveness of the different management practices
of leprosy patients, as well as to re-visit clinical practice guidelines in
managing multibacillary leprosy patients to encourage, if not ensure,
good treatment adherence.
The duration of treatment for multibacillary leprosy patients is
sometimes extended by their attending physicians when the latter believe

that reduction in BI levels after 12 months of treatment is insufﬁcient
(i.e., ‘persisters’), or that relapse is highly likely [9, 10]. This practice of
extending treatment beyond 12 months is based on the guidelines of the
Northern Territories of Australia [10] and the United States [27], which
suggest that treatment duration be extended up to 24 months to ensure
that ‘persisters’ and relapses are minimized. In this study, physicians in
Hospitals B and C were more likely to extend the duration of treatment of
their multibacillary leprosy patients compared to doctors in Hospital A.
This is despite the most recent treatment guidelines of the WHO which
prescribes that MDT should only be taken for 12 months [10]. Currently,
there is conﬂicting evidence on the supposed reduction in the risk of
relapse as a result of extending MDT to more than the prescribed 12
months duration [27, 28, 29, 30, 31, 32]. However, there is evidence that
the incidence, severity, and duration of leprosy reactions are decreased
by prolonging the duration of MDT to two years [33]. On the other hand,
it is also worth considering that extending the duration of treatment
would entail more MDT doses per patient. Given that the supply of MDT
is limited, especially in low-income settings, extending the duration of
treatment of many patients might lead to MDT shortage. MDT shortage
has been frequently mentioned to adversely affect treatment adherence
[1, 12]. Nevertheless, these controversies in treatment duration
demonstrate the need for studies that look at costs and beneﬁts of
treatment extension vis-a-vis the risk of relapse, reactions, and/or being a
‘persister’. Such studies are essential to make deﬁnite recommendations
on how multibacillary leprosy patients, especially those with high BI,
should be managed after completing the prescribed 12 months of MDT
[9, 27].
The prevention of treatment default can be approached from
multiple perspectives, including facility-based efforts to encourage
treatment adherence. Healthcare providers at Hospital A send periodic
Short Messaging Service (SMS) to remind their patients to seek
treatment [9]. This could partly explain why the hospital had the
lowest rate of treatment default and the highest rate of treatment
completion. The use of SMS to improve treatment adherence has been
found to be effective among tuberculosis patients [34], but similar
studies among leprosy patients are absent. Due to disruptions brought
about by the COVID-19 pandemic, we further anticipate a greater role

Figure 2. Treatment default pattern of the cohort (n ¼ 1,034).
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Table 4. Rates of default and results of log-rank test for each exposure stratum (n ¼ 1,034).
Exposure variables

Number (%) of Defaulters

Person-time (100 person-months)

Rate of treatment default (95% CI)

Hospital
A

79 (33.2)

27.37

2.89 (2.32–3.60)

B

41 (41.4)

16.21

2.53 (1.86–3.44)

C

263 (37.7)

79.29

3.32 (2.94–3.74)

143 (39.9)

40.62

3.52 (2.99–4.15)

Age Group
15–29

p-value of logrank test
0.37

0.21

30–44

133 (34.5)

47.55

2.80 (2.36–3.32)

45þ

107 (36.9)

34.69

3.08 (2.55–3.73)

Male

291 (37.8)

92.44

3.15 (2.81–3.53)

Female

92 (34,7)

30.42

3.02 (2.47–3.71)

Within Metro Manila

229 (36.2)

75.57

3.03 (2.66–3.45)

Outside Metro Manila

154 (38.4)

47.29

3.26 (2.78–3.81)

37 (26.6)

15.94

2.32 (1.68–3.20)

Sex

0.53

Place of residence

0.50

Initial Bacterial Index Value
0

0.14

1–3

141 (35.6)

43.47

3.24 (2.75–3.83)

4-6þ

151 (38.6)

50.24

3.01 (2.56–3.53)

Missing

54 (50.0)

13.22

4.09 (3.13–5.33)

No treatment extension

352 (41.1)

80.93

4.35 (3.92–4.83)

Yes, treatment was extended

31 (17.5)

41.93

0.74 (0.52–1.05)

<0.01

Treatment extension

addressing stigma can all be effective strategies to improve treatment
adherence [6, 36].
A strength of our study is the use of a cohort design, with data from
more than 1,000 patients and 12,000 person-months of follow-up, which
allowed us to quantify, with relatively precise conﬁdence intervals, the
extent of and the correlates of treatment adherence [37]. We also
considered treatment completion and treatment default as separate

of e-health interventions in improving medication adherence [35].
However, such efforts are encumbered by the reluctance of some patients to provide accurate contact details to health providers which
prevent the latter from sending reminders to patients about their clinic
visit schedules [9]. In the end, improving health worker-patient relationship, family/community involvement, more effective patient
counseling, patient information, education and communication, and

Table 5. Association of hospital, age category, sex, address, initial BI category, and treatment extension, with treatment default.
0–6 mos follow-up (n ¼ 902)

Crude rate ratio
Crude rate ratio (95% CI)

p-value

Adjusteda Hazard Ratio (95% CI)

>6 mos follow-up (n ¼ 677)
p-value

Adjustedb Hazard Ratio (95% CI)

p- value

Hospital
A

1 (baseline)

1 (baseline)

1 (baseline)

B

0.88 (0.60–1.28)

0.49

(excluded)

2.80 (1.08–7.30)

0.04

C

1.15 (0.89–1.48)

0.28

1.02 (0.75–1.38)

0.91

1.56 (0.94–2.58

0.08

1.00c (0.98–1.01)

Age Group
15–29

1 (baseline)

30–44

0.79 (0.63–1.01)

0.06

0.72 (0.53–0.99)

1 (baseline)
0.04

1 (baseline)

45þ

0.88 (0.68–1.13)

0.30

0.94 (0.68–1.30)

0.71

0.74

0.90 (0.66–1.23)

0.49

1.02 (0.78–1.34)

1.02c (0.95–1.10)

0.79

Sex
Male

1 (baseline)

Female

0.96 (0.76–1.21)

1 (baseline)

1 (baseline)
0.52

0.84 (0.52–1.35)

0.89

0.94 (0.63–1.40)

0.57

1.15c (1.03–1.29)

0.46

Address
Within Metro Manila

1 (baseline)

Outside Metro Manila

1.08 (0.88–1.32)

1 (baseline)

1 (baseline)
0.78

Initial BI
0.00

1 (baseline)

0.01–3.99

1.40 (0.97–2.00)

0.07

1 (baseline)

4.00þ

1.30 (0.90–1.86)

0.16

1 (baseline)
0.01

Treatment extension
Not extended

1 (baseline)

Extended

0.17 (0.12–0.25)

a
b
c

<0.01

1 (baseline)

1 (baseline)

(excluded)

0.19 (0.10–0.36)

Adjusted for Hospital (but excluding Hospital B), Age Group, Sex, Address, and Initial BI.
Adjusted for Hospital, Age Group, Sex, Address, Initial BI, and Treatment Extension.
Common linear effect.
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improve. The leprosy control program should be able to manage continuity of patient care by coming up with a centralized database of patients
and improving the patient referral system between treatment facilities.
Protocols for transferring to other treatment facilities should be emphasized to patients at the start of treatment. Future studies can build on our
research by doing a prospective cohort study that would address the
weaknesses of our study including possible selection bias, residual confounding, and limited generalizability. Future studies could also investigate the management of multibacillary leprosy patients after 12 months
of MDT, especially those who still have high BI, to come up with clear
recommendations on their duration of treatment and how they should be
managed.

outcomes because we wanted to identify possible points of intervention
to encourage treatment completion and prevent treatment default; two
outcomes which may not necessarily measure the same facet of treatment
adherence.
Our study has several limitations. Substantial missing data on subsequent BI readings, as well as lack of data on the number of patients seen
by each hospital per year, implies that the state of record-keeping is poor.
As a result, we cannot rule out selection bias as a result of including only
available records in the analysis. Furthermore, around 10% of respondents were not included in the regression analyses due to missing
data on initial BI. This may have also resulted to selection bias if absence
of data on BI is related to either treatment completion or defaulting. This
limitation highlights the need to improve patient-record keeping and if
necessary, re-train healthcare providers. In addition to selection bias,
misclassiﬁcation could also be a problem in our study. Some patients
failed to notify the hospital when they transferred to other health facility,
and as a result, these patients are erroneously classiﬁed as ‘defaulters’ by
the hospital. As a result, our study also classiﬁed these patients as ‘defaulters’, when in fact, they should be classiﬁed as ‘transferees’. Therefore, the number of those who dropped out from treatment may be
overestimated, while the number of those who left may be artiﬁcially
low. Since it is impossible to ascertain the true treatment status of some
patients (i.e., whether they really defaulted or just went to other clinics),
the effect of this misclassiﬁcation on the results of the study cannot be
ascertained. More importantly, these misclassiﬁed patients artiﬁcially
inﬂate the prevalence of leprosy in the country because they are counted
twice. To address this problem, we recommend that patients should be
informed early about proper procedures to take in case they need to
transfer to other health facilities. Doing this will hopefully reduce undocumented transfers and improve the accuracy of leprosy statistics in
the Philippines. A centralized registry of leprosy patients that is accessible throughout the country can also help address this problem. Lastly,
our study may also have residual confounding of the results as data on
many of the variables associated with treatment adherence (e.g., socioeconomic status, education, occurrence of adverse drug reactions, erythema nodosum leprosum, and leprosy reactions, etc.) were not
collected. Thus, the effect of these variables on the outcomes were not
controlled for in the regression analysis.

6. Other information
The results of this study have been presented orally in the 20th International Leprosy Congress held at Manila, Philippines on September
10–13, 2019.
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